Welcome to the new SADS site.
Click Here
to report any problems.
SADS Foundation USA
SADS Foundation Canada
SADS Foundation UK
SADS Foundation Netherlands
SADS Foundation China
SADS Foundation Hong Kong
Search for:
Log in
Supporting Families.
Saving Lives.
Sign-up for our
Enewsletter
here
.
SADS International
SADS Channel Blog
About Us
Contact Us
Library
Advocacy
Schools
Medical Professionals
Get Involved
Living with SADS
Research
Home
|
News
|
FDA Issues Safety Notice about Zofran
FDA Issues Safety Notice about Zofran
7/9/2012
As you may already have heard, the FDA informed healthcare professionals and the public that preliminary results from a recently completed clinical study suggest that a 32 mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) may prolong the QT interval which could pre-dispose patients to develop Torsades de Pointes.
The FDA will evaluate the final study results, when available, and will work with GlaxoSmithKline to explore an alternative single dose regimen that is both safe and effective for the prevention of chemotherapy-induced nausea and vomiting. This information does not change the recommended lower dose intravenous ondansetron used to prevent post-operative nausea and vomiting.
Though the new information on QT prolongation does not change any of the recommended oral dosing regimens for ondansetron, we recommend reviewing the following
paper
from the New England Journal of Medicine, which suggests there may be risks involved with the oral use of ondansetron.
Ray WA, Murray KT, et al. Azithromycin and the risk of cardiovascular death. NEJM 2012 May 17;366(20):1881-90.
Ondansetron (Zofran) is already included on the
Drugs to Avoid list
for people diagnosed with Long QT Syndrome.
Click here for more information from the FDA regarding this issue.
If you have any questions, please do not hesitate to contact us at 800-STOP-SAD or
Christine@sads.org
.
Back To News Page
Whats New
SADSConnect
TSA
Donate
About Us
Advocacy
International Partners
Schools
Dropbox
Medical Professionals
Get Involved
Library
Living with SADS
MatReqTest
Medical Professional Education
Research
Paypal Success
Paypal Failure
Thank you for your donation!
Volunteer to Fight SADS!
Overview of SADS Conditions
Online Community
SADS Online Support Community
Share Your Story
Stories: Living & Thriving with SADS
Stories: Forever in our Hearts
Enews Archives & Sign up
Find it Fast
Family Registration
Find a Physician
International SADS
Request Materials
Risk Assessment
Genetic Testing
Our Partners
Warning Signs
Family history of unexpected, unexplained sudden death under age 40.
Fainting or seizure during exercise, excitement or startle.
Consistent or unusual chest pain &/or shortness of breath during exercise.